Titre : Mastocytose cutanée

Mastocytose cutanée : Questions médicales fréquentes

Termes MeSH sélectionnés :

Complement C5a
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Mastocytose cutanée : Questions médicales les plus fréquentes", "headline": "Mastocytose cutanée : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Mastocytose cutanée : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-08-04", "dateModified": "2025-05-01", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Mastocytose cutanée" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Mastocytose", "url": "https://questionsmedicales.fr/mesh/D008415", "about": { "@type": "MedicalCondition", "name": "Mastocytose", "code": { "@type": "MedicalCode", "code": "D008415", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C20.762.750" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Mastocytome cutané", "alternateName": "Mastocytoma, Skin", "url": "https://questionsmedicales.fr/mesh/D054705", "about": { "@type": "MedicalCondition", "name": "Mastocytome cutané", "code": { "@type": "MedicalCode", "code": "D054705", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C20.762.750.563.500" } } }, { "@type": "MedicalWebPage", "name": "Urticaire pigmentaire", "alternateName": "Urticaria Pigmentosa", "url": "https://questionsmedicales.fr/mesh/D014582", "about": { "@type": "MedicalCondition", "name": "Urticaire pigmentaire", "code": { "@type": "MedicalCode", "code": "D014582", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C20.762.750.563.850" } } } ], "about": { "@type": "MedicalCondition", "name": "Mastocytose cutanée", "alternateName": "Mastocytosis, Cutaneous", "code": { "@type": "MedicalCode", "code": "D034701", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Magdalena Lange", "url": "https://questionsmedicales.fr/author/Magdalena%20Lange", "affiliation": { "@type": "Organization", "name": "Department of Dermatology, Venereology and Allergology, Medical University of Gdańsk, 80-211 Gdańsk, Poland." } }, { "@type": "Person", "name": "Karin Hartmann", "url": "https://questionsmedicales.fr/author/Karin%20Hartmann", "affiliation": { "@type": "Organization", "name": "Allergologische Poliklinik, Klinik für Dermatologie, Universitätsspital Basel, Petersgraben 4, 4031, Basel, Schweiz. karin.hartmann@usb.ch." } }, { "@type": "Person", "name": "Knut Brockow", "url": "https://questionsmedicales.fr/author/Knut%20Brockow", "affiliation": { "@type": "Organization", "name": "Department of Dermatology and Allergy Biederstein, School of Medicine and Health, Technical University of Munich, 80802 Munich, Germany." } }, { "@type": "Person", "name": "Roman J Nowicki", "url": "https://questionsmedicales.fr/author/Roman%20J%20Nowicki", "affiliation": { "@type": "Organization", "name": "Department of Dermatology, Venereology and Allergology, Medical University of Gdańsk, 80-211 Gdańsk, Poland." } }, { "@type": "Person", "name": "Olivier Hermine", "url": "https://questionsmedicales.fr/author/Olivier%20Hermine", "affiliation": { "@type": "Organization", "name": "Department of Hematology and Mastocytosis Expert Centre (CEREMAST), Necker Children's Hospital and Paris Descartes University, Assistance Publique Hôpitaux de Paris, Paris, France. Electronic address: ohermine@gmail.com." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the phase 2 PANAMO trial.", "datePublished": "2022-12-24", "url": "https://questionsmedicales.fr/article/36566174", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12931-022-02278-1" } }, { "@type": "ScholarlyArticle", "name": "The case for complement component 5 as a target in neurodegenerative disease.", "datePublished": "2023-02-17", "url": "https://questionsmedicales.fr/article/36786123", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/14728222.2023.2177532" } }, { "@type": "ScholarlyArticle", "name": "Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1.", "datePublished": "2023-12-01", "url": "https://questionsmedicales.fr/article/37824211", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1172/JCI168277" } }, { "@type": "ScholarlyArticle", "name": "The C5aR1 complement receptor: A novel immunomodulator of insulin action in skeletal muscle.", "datePublished": "2023-10-26", "url": "https://questionsmedicales.fr/article/37890688", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.cellsig.2023.110944" } }, { "@type": "ScholarlyArticle", "name": "Thinking inside the box: intracellular roles for complement system proteins come into focus.", "datePublished": "2023-01-17", "url": "https://questionsmedicales.fr/article/36650365", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41416-022-02116-7" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Maladies du système immunitaire", "item": "https://questionsmedicales.fr/mesh/D007154" }, { "@type": "ListItem", "position": 3, "name": "Troubles de l'activation mastocytaire", "item": "https://questionsmedicales.fr/mesh/D000090362" }, { "@type": "ListItem", "position": 4, "name": "Mastocytose", "item": "https://questionsmedicales.fr/mesh/D008415" }, { "@type": "ListItem", "position": 5, "name": "Mastocytose cutanée", "item": "https://questionsmedicales.fr/mesh/D034701" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Mastocytose cutanée - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Mastocytose cutanée", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-10", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Mastocytose cutanée", "description": "Comment diagnostique-t-on la mastocytose cutanée ?\nQuels tests sont utilisés pour confirmer la mastocytose ?\nLes symptômes sont-ils suffisants pour le diagnostic ?\nLa mastocytose cutanée est-elle confondue avec d'autres maladies ?\nQuel rôle joue l'historique médical dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D034701?mesh_terms=Complement+C5a&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Mastocytose cutanée", "description": "Quels sont les symptômes courants de la mastocytose cutanée ?\nLa mastocytose cutanée provoque-t-elle des douleurs ?\nLes symptômes varient-ils d'une personne à l'autre ?\nY a-t-il des symptômes systémiques associés ?\nLes lésions cutanées sont-elles contagieuses ?", "url": "https://questionsmedicales.fr/mesh/D034701?mesh_terms=Complement+C5a&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Mastocytose cutanée", "description": "Peut-on prévenir la mastocytose cutanée ?\nLes allergènes peuvent-ils aggraver la condition ?\nFaut-il éviter certains médicaments ?\nL'évitement du stress aide-t-il ?\nLes soins de la peau sont-ils importants ?", "url": "https://questionsmedicales.fr/mesh/D034701?mesh_terms=Complement+C5a&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Mastocytose cutanée", "description": "Quels traitements sont disponibles pour la mastocytose cutanée ?\nLes antihistaminiques sont-ils efficaces ?\nLa photothérapie est-elle une option de traitement ?\nLes traitements sont-ils permanents ?\nDes traitements alternatifs existent-ils ?", "url": "https://questionsmedicales.fr/mesh/D034701?mesh_terms=Complement+C5a&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Mastocytose cutanée", "description": "Quelles complications peuvent survenir avec la mastocytose cutanée ?\nLa mastocytose cutanée peut-elle évoluer vers une forme plus grave ?\nLes complications sont-elles fréquentes ?\nComment gérer les complications ?\nLes complications affectent-elles la qualité de vie ?", "url": "https://questionsmedicales.fr/mesh/D034701?mesh_terms=Complement+C5a&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Mastocytose cutanée", "description": "Quels sont les facteurs de risque de la mastocytose cutanée ?\nL'âge joue-t-il un rôle dans la mastocytose cutanée ?\nLes femmes sont-elles plus touchées que les hommes ?\nLes maladies auto-immunes augmentent-elles le risque ?\nL'exposition à des produits chimiques est-elle un facteur ?", "url": "https://questionsmedicales.fr/mesh/D034701?mesh_terms=Complement+C5a&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostique-t-on la mastocytose cutanée ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'examen clinique et la biopsie cutanée pour détecter les mastocytes." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour confirmer la mastocytose ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins pour mesurer les niveaux de tryptase peuvent être effectués." } }, { "@type": "Question", "name": "Les symptômes sont-ils suffisants pour le diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Non, les symptômes doivent être corroborés par des examens histologiques." } }, { "@type": "Question", "name": "La mastocytose cutanée est-elle confondue avec d'autres maladies ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut être confondue avec d'autres affections cutanées comme l'urticaire." } }, { "@type": "Question", "name": "Quel rôle joue l'historique médical dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'historique médical aide à identifier des antécédents d'allergies ou d'autres maladies liées." } }, { "@type": "Question", "name": "Quels sont les symptômes courants de la mastocytose cutanée ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des démangeaisons, des rougeurs et des lésions cutanées." } }, { "@type": "Question", "name": "La mastocytose cutanée provoque-t-elle des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut provoquer des douleurs localisées, surtout en cas de lésions étendues." } }, { "@type": "Question", "name": "Les symptômes varient-ils d'une personne à l'autre ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'intensité et la nature des symptômes peuvent varier considérablement." } }, { "@type": "Question", "name": "Y a-t-il des symptômes systémiques associés ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes systémiques comme des nausées peuvent survenir dans certains cas." } }, { "@type": "Question", "name": "Les lésions cutanées sont-elles contagieuses ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Non, les lésions cutanées de la mastocytose ne sont pas contagieuses." } }, { "@type": "Question", "name": "Peut-on prévenir la mastocytose cutanée ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de méthode de prévention spécifique pour la mastocytose cutanée." } }, { "@type": "Question", "name": "Les allergènes peuvent-ils aggraver la condition ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à certains allergènes peut aggraver les symptômes." } }, { "@type": "Question", "name": "Faut-il éviter certains médicaments ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments peuvent déclencher des réactions chez les patients sensibles." } }, { "@type": "Question", "name": "L'évitement du stress aide-t-il ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Gérer le stress peut aider à réduire les poussées de symptômes chez certains patients." } }, { "@type": "Question", "name": "Les soins de la peau sont-ils importants ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des soins appropriés de la peau peuvent aider à minimiser les irritations." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour la mastocytose cutanée ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des antihistaminiques et des corticostéroïdes topiques." } }, { "@type": "Question", "name": "Les antihistaminiques sont-ils efficaces ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils aident à réduire les démangeaisons et les rougeurs." } }, { "@type": "Question", "name": "La photothérapie est-elle une option de traitement ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la photothérapie peut être utilisée pour traiter les lésions cutanées." } }, { "@type": "Question", "name": "Les traitements sont-ils permanents ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Non, les traitements visent à gérer les symptômes, pas à guérir la maladie." } }, { "@type": "Question", "name": "Des traitements alternatifs existent-ils ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Certaines personnes explorent des traitements alternatifs, mais leur efficacité n'est pas prouvée." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec la mastocytose cutanée ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des infections cutanées peuvent survenir en raison de lésions." } }, { "@type": "Question", "name": "La mastocytose cutanée peut-elle évoluer vers une forme plus grave ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Dans de rares cas, elle peut évoluer vers une mastocytose systémique." } }, { "@type": "Question", "name": "Les complications sont-elles fréquentes ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les complications ne sont pas fréquentes mais peuvent survenir chez certains patients." } }, { "@type": "Question", "name": "Comment gérer les complications ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "La gestion des complications nécessite souvent une consultation spécialisée." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent affecter la qualité de vie en raison de l'inconfort." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque de la mastocytose cutanée ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux et des allergies cutanées." } }, { "@type": "Question", "name": "L'âge joue-t-il un rôle dans la mastocytose cutanée ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la mastocytose cutanée est plus fréquente chez les enfants et les jeunes adultes." } }, { "@type": "Question", "name": "Les femmes sont-elles plus touchées que les hommes ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Non, la mastocytose cutanée affecte les hommes et les femmes de manière égale." } }, { "@type": "Question", "name": "Les maladies auto-immunes augmentent-elles le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines maladies auto-immunes peuvent augmenter le risque de mastocytose." } }, { "@type": "Question", "name": "L'exposition à des produits chimiques est-elle un facteur ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à certains produits chimiques peut être un facteur de risque." } } ] } ] }

Sources (1656 au total)

Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the phase 2 PANAMO trial.

We recently reported in the phase 3 PANAMO trial that selectively blocking complement 5a (C5a) with vilobelimab led to improved survival in critically ill COVID-19 patients. C5a is an important contri...

The case for complement component 5 as a target in neurodegenerative disease.

Complement-based drug discovery is undergoing a renaissance, empowered by new advances in structural biology, complement biology and drug development. Certain components of the complement pathway, par... We will discuss the evidence supporting C5 as a target in neurodegenerative disease, along with the current progress in developing different classes of C5 inhibitors and the gaps in knowledge that wil... Validation of C5 as a therapeutic target for neurodegenerative disease would represent a major step forward for complement therapeutics research and has the potential to furnish disease-modifying drug...

Different Complement Activation Patterns Following C5 Cleavage in MOGAD and AQP4-IgG+NMOSD.

In myelin oligodendrocyte glycoprotein IgG-associated disease (MOGAD) and aquaporin-4 IgG+ neuromyelitis optica spectrum disorder (AQP4+NMOSD), the autoantibodies are mainly composed of IgG1, and comp... CSF-C3a, CSF-C4a, CSF-C5a, and CSF-C5b-9 levels during the acute phase before treatment in patients with MOGAD (n = 12), AQP4+NMOSD (n = 11), multiple sclerosis (MS) (n = 5), and noninflammatory neuro... CSF-C3a and CSF-C5a levels were significantly higher in MOGAD (mean ± SD, 5,629 ± 1,079 pg/mL and 2,930 ± 435.8 pg/mL) and AQP4+NMOSD (6,017 ± 3,937 pg/mL and 2,544 ± 1,231 pg/mL) than in MS (1,507 ± ... The complement pathway is activated in both MOGAD and AQP4+NMOSD, but MAC formation is lower in MOGAD, particularly in those with mild attacks, than in AQP4+NMOSD. These findings may have pathogenetic...

Serum Depletion of Complement Component 5a Is Associated With Increased Inflammation and Poor Clinical Outcomes in Patients With Perianal Fistulas.

Persistent disease is a significant issue in the management of perianal fistulas, with up to 50% of patients requiring additional treatment after surgery.... This study aimed to identify a novel prognostic modality in hopes of risk-stratifying patients for persistent disease following corrective surgery.... This was a retrospective study based on prospectively collected data using a combination of histopathology, high-throughput proteomic arrays, and ELISA-based methods.... This study used data obtained from patients who underwent corrective surgery for perianal fistulas at the University of Illinois Hospital between June 2019 and July 2020.... A cohort of 22 consecutive patients who had corrective surgery for perianal fistulas were included in this study. The patients were divided into 2 groups: those with resolving fistulas (N = 13) and th... Nonresolving fistulas were determined by disease representation within 2 months of corrective surgery.... Serum samples from patients with persistent perianal fistulas displayed a consistent decrease in the expression of complement pathway component C5a compared with either healthy controls or patients wi... This study was limited by its retrospective design, relatively small sample size, and single-center data analysis.... These results suggest that C5a is modestly depleted in patients with nonresolving forms of disease and traffics to the site of tissue damage and inflammation. Accordingly, serum C5a warrants continued... ANTECEDENTES:La persistencia de la enfermedad es un problema significativo en el manejo de las fístulas perianales, presente hasta en el 50 % de los pacientes después de la cirugía y que requieren tra...

Correlation of serum complement factor 5a level with inflammatory response and cognitive function in patients with Alzheimer's disease of different severity.

Alzheimer's disease (AD) is a common cause of dementia. Serum complement factor 5a (C5a) is exceedingly implicated in AD. We explored the role of C5a levels in AD patients of different severity.... Mild, moderate, and severe AD patients, and healthy controls were included. C5a and pro-inflammatory factor (TNF-α, IL-1β, IL-6, CRP) levels were assessed by ELISA, and cognitive function was evaluate... Serum C5a, TNF-α, IL-1β, IL-6 and CRP levels were raised, and MMSE score was lowered in AD. Serum C5a, TNF-α, IL-1β, IL-6 and CRP levels in severe AD patients were higher than those in mild/moderate A... Serum C5a level increased with AD severity, and its expression was positively correlated with serum pro-inflammatory factor levels, and negatively correlated with cognitive function....

Dysregulated complement activation during acute myocardial infarction leads to endothelial glycocalyx degradation and endothelial dysfunction via the C5a:C5a-Receptor1 axis.

Complement-mediated damage to the myocardium during acute myocardial infarction (AMI), particularly the late components of the terminal pathway (C5-convertase and C5b-9), have previously been characte... Samples of fifty-five patients with ST-elevation myocardial infarction (STEMI) vs. healthy controls were analyzed in this study. eGC components and C5a levels were determined via ELISA; NO levels were... Serum concentrations of eGC components and C5a were significantly increased during STEMI. Serum and solely C5a stimulation decreased eGC height and stiffness, indicating shedding of the eGC. C5a enhan... This study demonstrates that dysregulated C5a activation during AMI results in eGC damage with subsequent endothelial dysfunction and reduced NO bioavailability, indicating progressively developing va...